Cipher Pharmaceuticals Inc logo

CPH - Cipher Pharmaceuticals Inc Share Price

C$1.21 0.0  0.8%

Last Trade - 05/06/20

Micro Cap
Market Cap £19.1m
Enterprise Value £17.9m
Revenue £18.4m
Position in Universe 1010th / 2667
Unlock CPH Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Cipher Pharmaceuticals Inc revenues increased 15% to $5.9M. Net income before extraordinary items increased from $816K to $2.5M. Revenues reflect Product revenue increase of 41% to $2.6M, Licensing revenue remaining flat at $3.3M. Net income benefited from Selling, general and administrative decrease of 51% to $1.4M (expense), Interest expense decrease of 55% to $124K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CPH Revenue Unlock CPH Revenue

Net Income

CPH Net Income Unlock CPH Revenue

Normalised EPS

CPH Normalised EPS Unlock CPH Revenue

PE Ratio Range

CPH PE Ratio Range Unlock CPH Revenue

Dividend Yield Range

CPH Dividend Yield Range Unlock CPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CPH EPS Forecasts Unlock CPH Revenue
Profile Summary

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 9, 2004
Public Since February 25, 2004
No. of Shareholders: n/a
No. of Employees: 6
Sector Healthcare
Industry Pharmaceuticals
Exchange Toronto Stock Exchange
Shares in Issue 27,000,898
Free Float (0.0%)
Eligible for
CPH Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CPH
Upcoming Events for CPH
Frequently Asked Questions for Cipher Pharmaceuticals Inc
What is the Cipher Pharmaceuticals Inc share price?

As of 05/06/20, shares in Cipher Pharmaceuticals Inc are trading at C$1.21, giving the company a market capitalisation of £19.1m. This share price information is delayed by 15 minutes.

How has the Cipher Pharmaceuticals Inc share price performed this year?

Shares in Cipher Pharmaceuticals Inc are currently trading at C$1.21 and the price has moved by -6.25% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cipher Pharmaceuticals Inc price has moved by -2.32% over the past year.

What are the analyst and broker recommendations for Cipher Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Cipher Pharmaceuticals Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cipher Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Cipher Pharmaceuticals Inc next release its financial results?

Cipher Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Cipher Pharmaceuticals Inc dividend yield?

Cipher Pharmaceuticals Inc does not currently pay a dividend.

Does Cipher Pharmaceuticals Inc pay a dividend?

Cipher Pharmaceuticals Inc does not currently pay a dividend.

When does Cipher Pharmaceuticals Inc next pay dividends?

Cipher Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Cipher Pharmaceuticals Inc shares?

To buy shares in Cipher Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cipher Pharmaceuticals Inc?

Shares in Cipher Pharmaceuticals Inc are currently trading at C$1.21, giving the company a market capitalisation of £19.1m.

Where are Cipher Pharmaceuticals Inc shares listed? Where are Cipher Pharmaceuticals Inc shares listed?

Here are the trading details for Cipher Pharmaceuticals Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: CPH
What kind of share is Cipher Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Cipher Pharmaceuticals Inc is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cipher Pharmaceuticals Inc share price forecast 2020?

Shares in Cipher Pharmaceuticals Inc are currently priced at C$1.21. At that level they are trading at 51.85% discount to the analyst consensus target price of 0.00.

Analysts covering Cipher Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.268 for the next financial year.

How can I tell whether the Cipher Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cipher Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 13.56%. At the current price of C$1.21, shares in Cipher Pharmaceuticals Inc are trading at 10.3% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cipher Pharmaceuticals Inc PE Ratio?

The Cipher Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 3.88. The shares are currently trading at C$1.21.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Cipher Pharmaceuticals Inc?

Cipher Pharmaceuticals Inc's management team is headed by:

Craig Mull - CHM
Robert Tessarolo - PRE
Nadine Jutlah - CFO
Louise Blythe - VPR
Lorne Markowitz - VPR
Ralph Bohrer - CEX
Joan Chypyha - CEX
Linda Angaritis - VPR
Joseph Pecora - CEX
John Mull - DRC
Harold Wolkin - DRC
Stefan Aigner - IND
Thomas Wellner - IND
Lynne Bulger - VPR
Christian Godin - DRC
Who are the major shareholders of Cipher Pharmaceuticals Inc?

Here are the top five shareholders of Cipher Pharmaceuticals Inc based on the size of their shareholding:

Mull (John D M.D.) Individual Investor
Percentage owned: 36.75% (9.92m shares)
Mull, Craig James Individual Investor
Percentage owned: 2.75% (742k shares)
Deboeck (Arthur Marie Joseph Ghislain) Individual Investor
Percentage owned: 0.91% (245k shares)
Taylor North American Equity Opportunities Fund Mutual Fund
Percentage owned: 0.9% (243k shares)
Taylor Asset Management Inc. Investment Advisor
Percentage owned: 0.9% (243k shares)
Similar to CPH
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.